Localization of Non-Factor VIII Sequence Involved in the Factor VIII Gene Inversion in Hemophilia A Dogs.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1146-1146
Author(s):  
Jay Nelson Lozier ◽  
Brian Weeks ◽  
Nahid Tayebi

Abstract There is a common gene inversion at the telomere of the canine X chromosome in which factor VIII intron 22 DNA recombines with homologous sequence outside the gene. This mutation disrupts factor VIII synthesis and causes severe hemophilia A in dogs, analogous to a common inversion seen in humans (Lozier et al, PNAS 2002 99:12991–6). This mutation appears to be the only spontaneous gene inversion in an animal that replicates a corresponding disease of humans. The coding region for canine factor VIII spans approximately 146 kb and is found at the telomere of the X chromosome between bases 126,063,525 and 125,917,394 in the canine genome project, version 46.2d. Much of the canine factor VIII intron 22 remains unsequenced and the presence of F8A (the putative site of recombination in the factor VIII gene) in this region is inferred from PCR and Southern blot analysis of BAC clones that encompass this region. We have therefore focused on localizing the non-factor VIII site of the recombination and have found its essential elements in sequence located telomeric (upstream) to the canine factor VIII coding start site. We have used the boxer canine genome sequence (version 46.2d) as a template and reference for sequence analysis of BAC clone 291M9 (from normal Doberman pinscher genomic DNA library RPCI-81). Comparison of >100,000 bp of sequence common to the boxer and Doberman in this region showed >99% identity between the two breeds as expected. The BAC clone 291M9 was previously shown by DNA fiber FISH to be the region outside the factor VIII gene that participates in the gene inversion. This clone contains both F8A sequence (the putative site of recombination) as well as the sequence (ch8) that replaces the last four exons of the factor VIII transcript in hemophilia A dogs after the inversion. F8A sequence found in the Doberman BAC clone 291M9 matches sequence starting at nucleotide 126,317,916, in the boxer canine genome project (from RPCI-82 boxer BAC clone XX-145E20). This is outside the factor VIII gene, and approximately 400,000,000 base pairs upstream/telomeric to F8A found within the factor VIII gene. Approximately 20 kb from F8A is ch8, the sequence spliced into the abnormal hemophilia A factor VIII mRNA. The 7.5 kb region where the F8A sequence is found is extremely rich in guanosine and cytosine nucleotides (73% GC content) and has at least six putative CpG islands (as identified by the EMBOSS CpG analysis software (http://www.ebi.ac.uk/emboss/cpgplot/). This is consistent with the finding that F8A gene sequences outside the human factor VIII gene are found in CpG islands. There may be additional copies of the canine F8A sequence in or near this region (as is the case for the human genome), since gaps remain in this region of the known genomic sequence. The high GC content and highly repetitive nature makes sequence analysis and assembly problematic. These properties are consistent with DNA that is susceptible to homologous recombination and gene inversion as is seen with hemophilia in dogs and man. Figure Figure

1987 ◽  
Author(s):  
D Lillicrap ◽  
A R Giles ◽  
J J A Holden ◽  
B N White

This study has assessed the relative benefits of restriction fragment length polymorphism (RFLP) linkage and coagulation testing in the diagnosis of carriers of hemophilia A. 221 samples from 55 families have been studied for intragenic and flanking RFLPs. All samples were tested for the Factor VIII intragenic Bell RFLP and for the flanking marker St 14. 83% of obligate carrier females were heterozygous at oneor both of these two polymorphicsites. However, only38% of these women were heterozygous at the intragenic site and might safely be offered prenatal diagnosis using this marker for the hemophilia mutation. Carrier diagnosis was obtained in 52% of 81 potential carriers tested. Diagnosis wasbased on intragenic RFLP information in only 48% of these cases. Genetic diagnosis was possible in 27 atrisk women from families with no prior history of hemophilia. Four of these women were diagnosed as carriers on the basis of a gross Factor VIII gene deletion and the remaining 23 women were identified as non-carriers by the Bell (11) and Stl4 (12) RFLP data. 39 women remained undiagnosed after gene analysis studies. 23 of these women were female relatives of sporadic hemophiliacs and thus RFLP segregation analysis was inappropriate. A further 9 potential carriers were undiagnosed because of homozygosity in key individuals in their families. In 31 potential carriers we have quantitated Factor VIII:C (one stage assay) and vWf:Ag (Laurell and ELISA) and derived probabilities for carrier status. In 3 women there was conflicting genetic and coagulation data. Meanwhile, in 12 undiagnosed women from sporadic families, carrier diagnostic probabilities of > 0.9 were obtained. These studies indicate that optimal carrier detection for hemophilia A requires more intragenic and closely linked RFLPs and the continuance of coagulation testing to assist women from sporadic families.


Author(s):  
J. Schröder ◽  
V. Ivaskevicius ◽  
S. Rost ◽  
A. Müller ◽  
H.-H. Brackmann ◽  
...  

2010 ◽  
Vol 8 (11) ◽  
pp. 2472-2477 ◽  
Author(s):  
C. J. BOOTH ◽  
M. B. BROOKS ◽  
S. ROCKWELL ◽  
J. W. MURPHY ◽  
H. M. RINDER ◽  
...  

Blood ◽  
2002 ◽  
Vol 100 (9) ◽  
pp. 3432-3432 ◽  
Author(s):  
Federica Riccardi ◽  
Annarita Tagliaferri ◽  
Cesare Manotti ◽  
Corrado Pattacini ◽  
Tauro Maria Neri

2007 ◽  
Vol 10 (23) ◽  
pp. 4299-4302 ◽  
Author(s):  
Habib Onsori ◽  
Mohammad Ali Hossein . ◽  
Sheideh Montaser-Kou . ◽  
Mohammad Asgharzadeh . ◽  
Abbas Ali Hosseinpou .

Stem Cells ◽  
1993 ◽  
Vol 11 (S1) ◽  
pp. 72-76 ◽  
Author(s):  
A. Křepelová ◽  
R. Brdicka ◽  
Z. Vorlová

2001 ◽  
Vol 12 (13) ◽  
pp. 1651-1661 ◽  
Author(s):  
J. Andrew Bristol ◽  
Angela Gallo-Penn ◽  
Julie Andrews ◽  
Neeraja Idamakanti ◽  
Michael Kaleko ◽  
...  

1999 ◽  
Vol 82 (08) ◽  
pp. 555-561 ◽  
Author(s):  
Douglas Jolly ◽  
Judith Greengard

IntroductionHemophilia A results from the plasma deficiency of factor VIII, a gene carried on the X chromosome. Bleeding results from a lack of coagulation factor VIII, a large and complex protein that circulates in complex with its carrier, von Willebrand factor (vWF).1 Severe hemophilia A (<1% of normal circulating levels) is associated with a high degree of mortality, due to spontaneous and trauma-induced, life-threatening and crippling bleeding episodes.2 Current treatment in the United States consists of infusion of plasma-derived or recombinant factor VIII in response to bleeding episodes.3 Such treatment fails to prevent cumulative joint damage, a major cause of hemophilia-associated morbidity.4 Availability of prophylactic treatment, which would reduce the number and severity of bleeding episodes and, consequently, would limit such joint damage, is limited by cost and the problems associated with repeated venous access. Other problems are associated with frequent replacement treatment, including the dangers of transmission of blood-borne infections derived from plasma used as a source of factor VIII or tissue culture or formulation components. These dangers are reduced, but not eliminated, by current manufacturing techniques. Furthermore, approximately 1 in 5 patients with severe hemophilia treated with recombinant or plasma-derived factor VIII develop inhibitory humoral immune responses. In some cases, new inhibitors have developed, apparently in response to unnatural modifications introduced during manufacture or purification.5 Gene therapy could circumvent most of these difficulties. In theory, a single injection of a vector encoding the factor VIII gene could provide constant plasma levels of factor in the long term. However, long-term expression after gene transfer of a systemically expressed protein in higher mammals has seldom been described. In some cases, a vector that appeared promising in a rodent model has not worked well in larger animals, for example, due to a massive immune response not seen in the rodent.6 An excellent review of early efforts at factor VIII gene therapy appeared in an earlier volume of this series.7 A summary of results from various in vivo experiments is shown in Table 1. This chapter will focus on results pertaining to studies using vectors based on murine retroviruses, including our own work.


Sign in / Sign up

Export Citation Format

Share Document